The combined application of siRNA and drugs to block the CCL2/CCR2–STAT3 axis can inhibit the activity of TAMs in the CSC niche, thus enhancing the phagocytic activity of macrophages and inhibiting tumor growth and metastasis [179]. Here, CCL2 is linked to neoplasm.